Farmas USA

DVAX

última bala: announces FDA acceptance for review of CRL for HEPLISAV-B. Pdufa August 10,2017

DVAX 

Bueno pues a tapar los dos GAP que tiene pendientes de tapar y ya con eso nos vamos a 16. asi que paciencia que he tenido, que parece me va a premiar o por lo menos me va a devolver parte de los 13k usd que en Septiembre me arrebato´ y que tradeandolo consequi bajar a 8k usd

Umm,,,,,

IBB

LABU

Mugi, a esto te referías con el  decay??

HZNP

No sé muy bien lo que tengo que ver en ese gráfico...jeje

Lo más ilustrativo del decay es ver su gráfica de largo plazo para ver como pierden aceite y tienden a 0. LABU y LABD empezaron en mayo 2015, en 154$ y en 42$ respectivamente, y ya están en 50$ y 10$. Uno ha perdido casi el 67% y el otro el 75%...

De ayer en el congreso:

Trump calls for faster approval of prescription drugs

http://thehill.com/policy/healthcare/321707-trump-calls-for-faster-approval-of-prescription-drugs

Trump to Congress: We must bring down drug prices 'immediately'

http://thehill.com/policy/healthcare/321706-trump-to-congress-we-must-bring-down-drug-prices-immediately

En resumen, lo tomo como positivo para las bios, y en concreto, cuando habla sobre Megan, me recuerda mucho al caso de FOLD

"Our slow and burdensome approval process at the Food and Drug Administration (FDA) keeps too many advances ... from reaching those in need," Trump said.

One of Trump's guests to the speech was Megan Crowley, who was diagnosed with Pompe disease, a rare genetic illness that weakens muscles.

"On receiving this news, Megan's dad, John, fought with everything he had to save the life of his precious child. He founded a company to look for a cure, and helped develop the drug that saved Megan's life," Trump said. 

"If we slash the restraints, not just at the FDA but across our government, then we will be blessed with far more miracles like Megan."

FOLD

Reports FY16 EPS loss of ($1.49). Misses on revenues.

Amicus Therapeutics (NASDAQ: FOLD): FY EPS of -$1.49

Revenue of $4.96M

Shares +5.86% PM.

Target Enrollment Achieved in Phase 1/2 Pompe Study – Additional Data Expected in 2Q17 and 3Q17

Phase 3 EB Program on Track for Topline Data in Mid-2017

PS: Tengo en mente ese corto a La Jolla. Espero a ver si me deja el mercado alcista. Gracias.